CERT Certara

Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation

Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation

Certara improves software capabilities by expanding into deep learning and data fabric

PRINCETON, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), today announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software which allows life sciences organizations to perform predictions and answer complex questions across structured and unstructured bio-medical information. The acquisition will elevate Certara’s software by bringing state-of-the-art artificial intelligence (AI) capabilities to its end-to-end platform.

“We are pleased to announce the acquisition of Vyasa, a cutting-edge company that will enhance existing Certara software platforms and further expand our capabilities across our product portfolios,” said William F. Feehery, Chief Executive Officer of Certara. “By incorporating AI into our suite of products, we are building capabilities that will continue to expand our leadership for biosimulation use cases in drug research and development.”

Formed in 2017, Vyasa software provides a novel AI-powered platform for organizations to integrate and analyze content across their entire enterprise data landscape. Vyasa’s leading product, LAYAR, a flexible and modular data fabric that evaluates quantitative data, text, and images, offers AI capabilities to support decisions in all phases of drug development.

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

Forward Looking Statements

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Certara’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to: (i) our ability to successfully integrate Vyasa into our existing organization; (ii) our ability to successfully integrate Vyasa products and technology into our existing products; (iii) our ability to retain key personnel from Vyasa or recruit additional qualified personnel; (iv) our ability to achieve operational synergies; (vi) our ability to demonstrate the benefits of combining Vyasa’s technology with our existing or new products and (vii) our ability to satisfy specific customer needs by combining Vyasa’s technology with our existing or new products. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. All information provided in this press release is as of the date of this press release, and Certara undertakes no duty to update such information, except as required under applicable law.

Investor Relations Contact:

David Deuchler

Gilmartin Group

Media Contact:

Daniel Yunger

Kekst CNC



EN
04/01/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE

Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Su...

Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster Solution delivers a 50% reduction in time spent drafting mapping specifications, according to internal measurements RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the availability of . The solution enables clinical and statistical programmers to efficiently create, reuse, and manage required data specifications for creating the CDISC Study Data Tabulation Model (SDTM) and Analysis Data Model (ADaM) datasets. These dataset...

 PRESS RELEASE

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: Baird Global Healthcare ConferenceDate and Time: Tuesday, September 9 at 10:15 a.m. ET Morgan Stanley 23rd Annual Global Healthcare ConferenceDate and Time: Wednesday, September 10 at 12:20 p.m. ET Live webcasts for each of the conferences will be available on Certara’s investor relations website at and will...

 PRESS RELEASE

Certara Reports Second Quarter 2025 Financial Results 

Certara Reports Second Quarter 2025 Financial Results  Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 million, compared to $93.3 million in the second quarter of 2024, representing growth of 12%. Software revenue was $46.7 million, compared to $38.2 million in the second quarter of 2024, representing growth of 22%.Service revenue ...

 PRESS RELEASE

Certara Simcyp® Simulator Becomes First and Only Software Platform to ...

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU. Certara is the first company to receive EMA qualification for a PBPK modeling platform, and Simcyp is the only software to hold this designation. The recognition follows a rigorous multi-year, collaborative engagement between ...

 PRESS RELEASE

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advan...

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-gene...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch